The University of Chicago Header Logo

Connection

David Rubin to Inflammatory Bowel Diseases

Back to Details
This is a "connection" page, showing publications David Rubin has written about Inflammatory Bowel Diseases.
David Rubin
Connection Strength
31.476
Inflammatory Bowel Diseases
  1. Increasing Exposure to Inflammatory Bowel Diseases Education in Gastroenterology Fellowship: The Pilot IBD 101 Experience. Inflamm Bowel Dis. 2025 Mar 03; 31(3):746-750.
    View in: PubMed
    Score: 0.587
  2. Artificial Intelligence in Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am. 2025 Apr; 35(2):367-387.
    View in: PubMed
    Score: 0.576
  3. Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2024 Dec; 69(12):4437-4445.
    View in: PubMed
    Score: 0.574
  4. Interrupting inflammatory bowel disease therapy: why, who, when and how to consider medication holidays. Expert Rev Gastroenterol Hepatol. 2024 Oct; 18(10):587-596.
    View in: PubMed
    Score: 0.572
  5. Overview to Challenges in IBD 2024-2029. Inflamm Bowel Dis. 2024 05 23; 30(Suppl 2):S1-S4.
    View in: PubMed
    Score: 0.556
  6. Endoscopy in Inflammatory Bowel Disease: Indications, Timing, and Biopsy Protocol. Gastrointest Endosc Clin N Am. 2025 Jan; 35(1):1-18.
    View in: PubMed
    Score: 0.555
  7. The Management of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1181-1185.
    View in: PubMed
    Score: 0.547
  8. Clinical Application of Intestinal Ultrasound in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2024 Feb; 26(2):31-40.
    View in: PubMed
    Score: 0.543
  9. At-home Disease Monitoring by Patient-performed Intestinal Ultrasound in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2023 12 05; 29(12):1997-1998.
    View in: PubMed
    Score: 0.539
  10. Common Instances of Low-value Care in Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2024 May; 22(5):923-932.
    View in: PubMed
    Score: 0.534
  11. Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 10 03; 29(10):1658-1661.
    View in: PubMed
    Score: 0.532
  12. Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
    View in: PubMed
    Score: 0.498
  13. Self-Reported Failure to Address Sexual Function in Patients With Inflammatory Bowel Disease by Gastroenterologists: Barriers and Areas for Improvement. Inflamm Bowel Dis. 2022 09 01; 28(9):1465-1468.
    View in: PubMed
    Score: 0.493
  14. IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis. 2022 May 11; 16(Supplement_2):ii42-ii53.
    View in: PubMed
    Score: 0.483
  15. Entering the Era of Disease Modification in Inflammatory Bowel Disease. Gastroenterology. 2022 04; 162(5):1367-1369.
    View in: PubMed
    Score: 0.475
  16. International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis. 2021 11 15; 27(12):1942-1953.
    View in: PubMed
    Score: 0.467
  17. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021 10; 161(4):1118-1132.
    View in: PubMed
    Score: 0.458
  18. New targets in inflammatory bowel disease therapy: 2021. Curr Opin Gastroenterol. 2021 07 01; 37(4):357-363.
    View in: PubMed
    Score: 0.455
  19. Using Wearable Biosensors to Predict Length of Stay for Patients with IBD After Bowel Surgery. Dig Dis Sci. 2022 03; 67(3):844-853.
    View in: PubMed
    Score: 0.447
  20. Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
    View in: PubMed
    Score: 0.443
  21. Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act. J Crohns Colitis. 2020 Dec 02; 14(12):1765-1768.
    View in: PubMed
    Score: 0.437
  22. Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician. Am J Gastroenterol. 2020 10; 115(10):1566-1569.
    View in: PubMed
    Score: 0.432
  23. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020 Jul; 159(1):350-357.
    View in: PubMed
    Score: 0.418
  24. Inpatient Management of Inflammatory Bowel Disease-Related Complications. Clin Gastroenterol Hepatol. 2020 05; 18(6):1346-1355.
    View in: PubMed
    Score: 0.411
  25. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol. 2019 12; 114(12):1904-1908.
    View in: PubMed
    Score: 0.408
  26. Proposal to Update the Curriculum in Inflammatory Bowel Diseases for Categorical Gastroenterology Fellows. Inflamm Bowel Dis. 2019 08 20; 25(9):1443-1449.
    View in: PubMed
    Score: 0.400
  27. Histologic Remission in Ulcerative Colitis: Are We There Yet? Am J Gastroenterol. 2019 05; 114(5):713-715.
    View in: PubMed
    Score: 0.392
  28. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
    View in: PubMed
    Score: 0.390
  29. The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. Inflamm Bowel Dis. 2019 02 21; 25(3):427-435.
    View in: PubMed
    Score: 0.386
  30. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018 11; 35(11):1746-1762.
    View in: PubMed
    Score: 0.378
  31. Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 04; 17(5):818-823.
    View in: PubMed
    Score: 0.374
  32. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
    View in: PubMed
    Score: 0.366
  33. Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply. Aliment Pharmacol Ther. 2018 05; 47(10):1423-1424.
    View in: PubMed
    Score: 0.365
  34. The use of tofacitinib in the treatment of inflammatory bowel disease. Immunotherapy. 2018 08; 10(10):837-849.
    View in: PubMed
    Score: 0.365
  35. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
    View in: PubMed
    Score: 0.360
  36. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
    View in: PubMed
    Score: 0.359
  37. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
    View in: PubMed
    Score: 0.333
  38. Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. Dig Dis Sci. 2016 10; 61(10):2972-2976.
    View in: PubMed
    Score: 0.325
  39. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep. 2016 Jan; 18(1):5.
    View in: PubMed
    Score: 0.311
  40. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Jul; 21(7):1709-18.
    View in: PubMed
    Score: 0.300
  41. Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease. Am J Gastroenterol. 2015 Sep; 110(9):1252-6.
    View in: PubMed
    Score: 0.295
  42. Can we improve on the "see one, do one, teach one" paradigm in training fellows to care for patients with inflammatory bowel disease? Inflamm Bowel Dis. 2015 Apr; 21(4):766-7.
    View in: PubMed
    Score: 0.295
  43. The rationale and growth of advanced training in inflammatory bowel disease. Gastroenterology. 2015 Apr; 148(4):696-700.
    View in: PubMed
    Score: 0.293
  44. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015 Apr; 9(4):312-7.
    View in: PubMed
    Score: 0.291
  45. Why it's time for updated U.S. colorectal cancer prevention guidelines in inflammatory bowel disease. Gastrointest Endosc. 2014 Nov; 80(5):849-51.
    View in: PubMed
    Score: 0.286
  46. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014 12; 8(12):1569-81.
    View in: PubMed
    Score: 0.284
  47. Fecal microbiota transplantation: an interest in IBD? Nestle Nutr Inst Workshop Ser. 2014; 79:101-14.
    View in: PubMed
    Score: 0.284
  48. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014 Jul; 24(3):353-65.
    View in: PubMed
    Score: 0.277
  49. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol. 2012 Jan 21; 18(3):197-204.
    View in: PubMed
    Score: 0.237
  50. Infectious proctitis: when to suspect it is not inflammatory bowel disease. Dig Dis Sci. 2012 Feb; 57(2):269-73.
    View in: PubMed
    Score: 0.232
  51. Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis. 2010 Jan; 16(1):125-33.
    View in: PubMed
    Score: 0.205
  52. Novel diagnostic and prognostic modalities in inflammatory bowel disease. Gastroenterol Clin North Am. 2009 Dec; 38(4):729-52.
    View in: PubMed
    Score: 0.204
  53. Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers. 2009 Aug; 13(4):495-503.
    View in: PubMed
    Score: 0.199
  54. An updated approach to dysplasia in IBD. J Gastrointest Surg. 2008 Dec; 12(12):2153-6.
    View in: PubMed
    Score: 0.187
  55. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis. 2008 Feb; 14(2):265-74.
    View in: PubMed
    Score: 0.180
  56. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Apr; 13(4):367-71.
    View in: PubMed
    Score: 0.169
  57. The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J Genet Couns. 2006 Dec; 15(6):465-76.
    View in: PubMed
    Score: 0.166
  58. Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Sep; 35(3):581-604.
    View in: PubMed
    Score: 0.163
  59. Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis. 2006 Jun; 12(6):497-502.
    View in: PubMed
    Score: 0.160
  60. The changing face of colorectal cancer in inflammatory bowel disease: progress at last! Gastroenterology. 2006 Apr; 130(4):1350-2.
    View in: PubMed
    Score: 0.158
  61. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025 Jun; 642(8067):458-466.
    View in: PubMed
    Score: 0.148
  62. Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response. Nat Rev Gastroenterol Hepatol. 2025 Jun; 22(6):438-452.
    View in: PubMed
    Score: 0.148
  63. Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design. Lancet Gastroenterol Hepatol. 2025 Jun; 10(6):593-604.
    View in: PubMed
    Score: 0.148
  64. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31; 12(1).
    View in: PubMed
    Score: 0.148
  65. Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device. Inflamm Bowel Dis. 2025 Mar 03; 31(3):647-654.
    View in: PubMed
    Score: 0.147
  66. Diagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic Review. Inflamm Bowel Dis. 2025 Mar 03; 31(3):812-842.
    View in: PubMed
    Score: 0.147
  67. Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross-Sectional Multi-Center Study. Arthritis Care Res (Hoboken). 2025 Jun; 77(6):777-784.
    View in: PubMed
    Score: 0.146
  68. Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2025 01 06; 31(1):63-71.
    View in: PubMed
    Score: 0.145
  69. Role of antibiotics in the management of inflammatory bowel disease: a review. Rev Gastroenterol Disord. 2005; 5 Suppl 3:S10-5.
    View in: PubMed
    Score: 0.145
  70. Risk of Common Neurological Disorders in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2024 11 04; 30(11):2195-2204.
    View in: PubMed
    Score: 0.143
  71. Management of Colorectal Neoplasia in IBD Patients: Current Practice and Future Perspectives. J Crohns Colitis. 2024 Oct 15; 18(10):1726-1735.
    View in: PubMed
    Score: 0.143
  72. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nat Med. 2024 Dec; 30(12):3555-3567.
    View in: PubMed
    Score: 0.143
  73. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 10 03; 30(10):1776-1787.
    View in: PubMed
    Score: 0.143
  74. Impact of a health-system specialty pharmacy on time to upadacitinib initiation. Am J Health Syst Pharm. 2024 Sep 23; 81(19):e594-e600.
    View in: PubMed
    Score: 0.142
  75. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
    View in: PubMed
    Score: 0.142
  76. Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care. Lancet. 2024 08 03; 404(10451):414-417.
    View in: PubMed
    Score: 0.139
  77. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. J Crohns Colitis. 2024 Apr 23; 18(4):548-559.
    View in: PubMed
    Score: 0.138
  78. Role of artificial intelligence in imaging and endoscopy for the diagnosis, monitoring and prognostication of inflammatory bowel disease: a scoping review protocol. BMJ Open Gastroenterol. 2023 12 11; 10(1).
    View in: PubMed
    Score: 0.135
  79. Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterol J. 2023 10; 11(8):797-806.
    View in: PubMed
    Score: 0.132
  80. Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation. Inflamm Bowel Dis. 2023 08 01; 29(8):1177-1190.
    View in: PubMed
    Score: 0.131
  81. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023 09; 8(9):853-859.
    View in: PubMed
    Score: 0.131
  82. Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. J Crohns Colitis. 2023 Jul 05; 17(7):1066-1078.
    View in: PubMed
    Score: 0.131
  83. Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023 Jun; 29(6):1520-1529.
    View in: PubMed
    Score: 0.130
  84. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). BMC Med Res Methodol. 2023 05 25; 23(1):129.
    View in: PubMed
    Score: 0.130
  85. Ultrasonographic Transmural Healing in Crohn's Disease. Am J Gastroenterol. 2023 06 01; 118(6):961-969.
    View in: PubMed
    Score: 0.128
  86. Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Crohns Colitis. 2023 Mar 18; 17(2):199-210.
    View in: PubMed
    Score: 0.128
  87. Intestinal Ultrasound in the Assessment and Management of Inflammatory Bowel Disease: Is It Ready for Standard Practice? Gastroenterology. 2023 05; 164(6):851-855.
    View in: PubMed
    Score: 0.127
  88. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. Clin Gastroenterol Hepatol. 2023 08; 21(9):2211-2221.
    View in: PubMed
    Score: 0.122
  89. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
    View in: PubMed
    Score: 0.122
  90. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022 07; 56(1):6-27.
    View in: PubMed
    Score: 0.121
  91. Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. Lancet Gastroenterol Hepatol. 2022 05; 7(5):390-391.
    View in: PubMed
    Score: 0.121
  92. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol Hepatol. 2022 07; 7(7):666-678.
    View in: PubMed
    Score: 0.120
  93. The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 11; 20(11):2427-2434.
    View in: PubMed
    Score: 0.120
  94. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterol. 2022 Feb 19; 22(1):71.
    View in: PubMed
    Score: 0.119
  95. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022 03; 7(3):254-261.
    View in: PubMed
    Score: 0.118
  96. Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2021 12 01; 116(12):2410-2418.
    View in: PubMed
    Score: 0.117
  97. Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
    View in: PubMed
    Score: 0.116
  98. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 12; 18(12):857-873.
    View in: PubMed
    Score: 0.115
  99. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol. 2021 07 01; 37(4):313-319.
    View in: PubMed
    Score: 0.114
  100. Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert Rev Gastroenterol Hepatol. 2021 Sep; 15(9):985-997.
    View in: PubMed
    Score: 0.113
  101. Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD. J Clin Gastroenterol. 2022 07 01; 56(6):529-535.
    View in: PubMed
    Score: 0.113
  102. Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. World J Gastroenterol. 2021 May 28; 27(20):2521-2530.
    View in: PubMed
    Score: 0.113
  103. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2021 05 17; 27(6):947-955.
    View in: PubMed
    Score: 0.113
  104. Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. Inflamm Bowel Dis. 2021 05 17; 27(6):836-847.
    View in: PubMed
    Score: 0.113
  105. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J. 2021 05; 9(4):451-460.
    View in: PubMed
    Score: 0.113
  106. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021 Apr; 70(4):635-640.
    View in: PubMed
    Score: 0.110
  107. COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions. Gastroenterology. 2021 04; 160(5):1447-1451.
    View in: PubMed
    Score: 0.110
  108. Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic. J Crohns Colitis. 2020 Oct 21; 14(14 Suppl 3):S774-S779.
    View in: PubMed
    Score: 0.108
  109. Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic. Gastroenterology. 2021 02; 160(3):639-644.
    View in: PubMed
    Score: 0.108
  110. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
    View in: PubMed
    Score: 0.108
  111. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3.
    View in: PubMed
    Score: 0.108
  112. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
    View in: PubMed
    Score: 0.107
  113. Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021 04; 70(4):796-802.
    View in: PubMed
    Score: 0.107
  114. An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI. Clin Gastroenterol Hepatol. 2021 12; 19(12):2524-2531.
    View in: PubMed
    Score: 0.107
  115. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62.
    View in: PubMed
    Score: 0.107
  116. Practical advice for management of inflammatory bowel diseases patients during the COVID-19 pandemic: World Endoscopy Organization Statement. Dig Endosc. 2020 Jul; 32(5):658-662.
    View in: PubMed
    Score: 0.106
  117. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther. 2020 07; 52(1):54-72.
    View in: PubMed
    Score: 0.105
  118. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.105
  119. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. Inflamm Bowel Dis. 2020 01 01; 26(1):1-10.
    View in: PubMed
    Score: 0.103
  120. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.
    View in: PubMed
    Score: 0.100
  121. IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. J Crohns Colitis. 2019 Jul 25; 13(7):884-893.
    View in: PubMed
    Score: 0.099
  122. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.099
  123. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019 05 16; 25(Suppl 2):S40-S47.
    View in: PubMed
    Score: 0.098
  124. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
    View in: PubMed
    Score: 0.098
  125. Legal Risks and Considerations Associated with Inflammatory Bowel Disease: A Primer. Am J Gastroenterol. 2018 11; 113(11):1577-1579.
    View in: PubMed
    Score: 0.095
  126. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017 Oct 01; 11(10):1180-1199.
    View in: PubMed
    Score: 0.088
  127. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
    View in: PubMed
    Score: 0.087
  128. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
    View in: PubMed
    Score: 0.087
  129. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci. 2017 04; 62(4):833-842.
    View in: PubMed
    Score: 0.085
  130. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
    View in: PubMed
    Score: 0.080
  131. Activation of the Renin-Angiotensin System Promotes Colitis Development. Sci Rep. 2016 06 08; 6:27552.
    View in: PubMed
    Score: 0.080
  132. Association between serrated epithelial changes and colorectal dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2016 Jul; 84(1):87-95.e1.
    View in: PubMed
    Score: 0.078
  133. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38.
    View in: PubMed
    Score: 0.076
  134. Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. Curr Gastroenterol Rep. 2014 Sep; 16(9):407.
    View in: PubMed
    Score: 0.071
  135. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8.
    View in: PubMed
    Score: 0.064
  136. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Mar; 37(5):546-54.
    View in: PubMed
    Score: 0.063
  137. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):286-92; quiz e24.
    View in: PubMed
    Score: 0.063
  138. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011 Jul; 60(7):937-43.
    View in: PubMed
    Score: 0.055
  139. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
    View in: PubMed
    Score: 0.055
  140. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
    View in: PubMed
    Score: 0.049
  141. Development of Luminescent Biosensors for Calprotectin. ACS Chem Biol. 2024 06 21; 19(6):1250-1259.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.